JP2019519488A - 透過性増強された医薬組成物 - Google Patents

透過性増強された医薬組成物 Download PDF

Info

Publication number
JP2019519488A
JP2019519488A JP2018558225A JP2018558225A JP2019519488A JP 2019519488 A JP2019519488 A JP 2019519488A JP 2018558225 A JP2018558225 A JP 2018558225A JP 2018558225 A JP2018558225 A JP 2018558225A JP 2019519488 A JP2019519488 A JP 2019519488A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
polymer
composition according
acid
polymer matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018558225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519488A5 (enExample
Inventor
マーク ショベル アレクサンダー
マーク ショベル アレクサンダー
マリー バージャン ステファニー
マリー バージャン ステファニー
ポール ワルガクキ ステファン
ポール ワルガクキ ステファン
Original Assignee
アクエスティブ セラピューティクス インコーポレイテッド
アクエスティブ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクエスティブ セラピューティクス インコーポレイテッド, アクエスティブ セラピューティクス インコーポレイテッド filed Critical アクエスティブ セラピューティクス インコーポレイテッド
Publication of JP2019519488A publication Critical patent/JP2019519488A/ja
Publication of JP2019519488A5 publication Critical patent/JP2019519488A5/ja
Priority to JP2023104610A priority Critical patent/JP2023134518A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018558225A 2016-05-05 2017-05-04 透過性増強された医薬組成物 Pending JP2019519488A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023104610A JP2023134518A (ja) 2016-05-05 2023-06-27 透過性増強された医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662331993P 2016-05-05 2016-05-05
US62/331,993 2016-05-05
PCT/US2017/031170 WO2017192923A1 (en) 2016-05-05 2017-05-04 Pharmaceutical compositions with enhanced permeation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023104610A Division JP2023134518A (ja) 2016-05-05 2023-06-27 透過性増強された医薬組成物

Publications (2)

Publication Number Publication Date
JP2019519488A true JP2019519488A (ja) 2019-07-11
JP2019519488A5 JP2019519488A5 (enExample) 2020-06-25

Family

ID=58708068

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018558225A Pending JP2019519488A (ja) 2016-05-05 2017-05-04 透過性増強された医薬組成物
JP2023104610A Pending JP2023134518A (ja) 2016-05-05 2023-06-27 透過性増強された医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023104610A Pending JP2023134518A (ja) 2016-05-05 2023-06-27 透過性増強された医薬組成物

Country Status (9)

Country Link
US (1) US20170290776A1 (enExample)
EP (1) EP3452024A1 (enExample)
JP (2) JP2019519488A (enExample)
KR (1) KR102536696B1 (enExample)
CN (1) CN109310647A (enExample)
BR (1) BR112018072467A2 (enExample)
CA (1) CA3022797A1 (enExample)
IL (2) IL262751B2 (enExample)
WO (1) WO2017192923A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019519487A (ja) * 2016-05-05 2019-07-11 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
JP2023502069A (ja) * 2019-11-14 2023-01-20 アクエスティブ セラピューティクス インコーポレイテッド マルチモーダルな組成物及び治療方法
JP2023546646A (ja) * 2020-08-28 2023-11-07 エルテーエス ローマン テラピー－ジステーメ アーゲー 粘膜の穿孔
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020500220A (ja) 2016-11-15 2020-01-09 クラリア ファーマ ホールディング エービー 医薬製剤
WO2018129499A1 (en) * 2017-01-09 2018-07-12 Verily Life Sciences Llc Systems and methods for wearable emergency drug injection devices
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
EP3687510A1 (en) * 2017-09-27 2020-08-05 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
CA3076815A1 (en) * 2017-09-27 2019-04-04 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
CN107903322B (zh) * 2017-10-10 2022-03-08 宜宾学院 一种基于黄樟素环氧化改性制备抗菌胶原的方法
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
US11648197B2 (en) 2018-06-28 2023-05-16 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs
CN112955124A (zh) * 2018-09-07 2021-06-11 阿奎蒂夫疗法公司 具有精确的活性物溶出谱的口腔膜组合物和剂型
AU2020373100A1 (en) * 2019-11-01 2022-05-19 Aquestive Therapeutics, Inc. Prodrug compositions and methods of treatment
CA3160750A1 (en) 2019-12-09 2021-06-17 Anthony Richard Gerardi Oral product comprising a cannabinoid
WO2022074127A2 (en) * 2020-10-08 2022-04-14 Catalent U.K. Swindon Zydis Limited Stable oral dispersible formulation for epinephrine and salts or solvates thereof
US11839602B2 (en) 2020-11-25 2023-12-12 Nicoventures Trading Limited Oral cannabinoid product with lipid component
JP2025029732A (ja) 2023-08-22 2025-03-07 三菱電機株式会社 ゲート駆動装置
CN120037250A (zh) * 2025-04-07 2025-05-27 江苏知原药业股份有限公司 一种伊维菌素外用药物组合物、制备方法及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006507277A (ja) * 2002-10-25 2006-03-02 ラボファーマ インコーポレイテッド ２４時間有効な持続放出トラマドール製剤
JP2008501019A (ja) * 2004-05-28 2008-01-17 ザース・インコーポレーテッド パニック発作を治療するためのシステム及び方法
WO2011010732A1 (ja) * 2009-07-23 2011-01-27 株式会社 イギス 皮膚外用剤組成物
JP2013530193A (ja) * 2010-07-06 2013-07-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｇａｂａ類似体及びオピオイドを含む新規胃内滞留型剤形
JP2019519487A (ja) * 2016-05-05 2019-07-11 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1357891A (en) 1920-07-15 1920-11-02 Henry S Murray Portable instantaneous water-heater
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20040096569A1 (en) * 2002-11-15 2004-05-20 Barkalow David G. Edible film products and methods of making same
US20050266085A1 (en) * 2004-05-28 2005-12-01 Warner Kevin S Gelled emulsion and microemulsion formulations for dermal drug delivery
US20070202163A1 (en) * 2005-09-09 2007-08-30 Mutasem Rawas-Qalaji Fast-disintegrating epinephrine tablets for buccal or sublingual administration
IL175338A0 (en) * 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
WO2013063614A1 (en) * 2011-10-28 2013-05-02 Sung-Yun Kwon Dissolving solid solution perforator patch for migraine treatment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006507277A (ja) * 2002-10-25 2006-03-02 ラボファーマ インコーポレイテッド ２４時間有効な持続放出トラマドール製剤
JP2008501019A (ja) * 2004-05-28 2008-01-17 ザース・インコーポレーテッド パニック発作を治療するためのシステム及び方法
WO2011010732A1 (ja) * 2009-07-23 2011-01-27 株式会社 イギス 皮膚外用剤組成物
JP2013530193A (ja) * 2010-07-06 2013-07-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｇａｂａ類似体及びオピオイドを含む新規胃内滞留型剤形
JP2019519487A (ja) * 2016-05-05 2019-07-11 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DRUG DISCOV TODAY, vol. Vol. 12, No. 23-24, JPN6021025187, 2007, pages 1061 - 1067, ISSN: 0005111130 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019519487A (ja) * 2016-05-05 2019-07-11 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物
US11191737B2 (en) 2016-05-05 2021-12-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12023309B2 (en) 2016-05-05 2024-07-02 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
JP2023502069A (ja) * 2019-11-14 2023-01-20 アクエスティブ セラピューティクス インコーポレイテッド マルチモーダルな組成物及び治療方法
JP2023546646A (ja) * 2020-08-28 2023-11-07 エルテーエス ローマン テラピー－ジステーメ アーゲー 粘膜の穿孔
JP7713006B2 (ja) 2020-08-28 2025-07-24 エルテーエス ローマン テラピー－ジステーメ アーゲー 粘膜の穿孔
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Also Published As

Publication number Publication date
KR102536696B1 (ko) 2023-05-25
WO2017192923A1 (en) 2017-11-09
IL262751B2 (en) 2025-07-01
CN109310647A (zh) 2019-02-05
IL318880A (en) 2025-04-01
KR20190005198A (ko) 2019-01-15
BR112018072467A2 (pt) 2019-02-19
CA3022797A1 (en) 2017-11-09
IL262751A (en) 2018-12-31
IL262751B1 (en) 2025-03-01
EP3452024A1 (en) 2019-03-13
JP2023134518A (ja) 2023-09-27
US20170290776A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
US12023309B2 (en) Enhanced delivery epinephrine compositions
JP2023134518A (ja) 透過性増強された医薬組成物
JP7431724B2 (ja) 増強された透過を有する医薬組成物
JP2023159150A (ja) 増強された送達のエピネフリン及びプロドラッグ組成物
US12433850B2 (en) Enhanced delivery epinephrine and prodrug compositions
US11273131B2 (en) Pharmaceutical compositions with enhanced permeation
US12427121B2 (en) Enhanced delivery epinephrine compositions
US20190022022A1 (en) Pharmaceutical compositions with enhanced permeation
US20180125977A1 (en) Enhanced delivery epinephrine compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230627

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230704

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250627

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250930